Andon

九安医疗

Tianjin Andon Medical Electronics Co., Ltd. (hereinafter referred to as “Andon Medical”) was founded in 1995 and is a global listed company in mobile medical services. The company adheres to two core strategies: promoting the “O+O” new model for diabetes diagnosis and care, and continuously introducing cost-effective blockbuster products on its new retail platform.

On June 10, 2010, the company went public on the SME Board of the Shenzhen Stock Exchange. The same year, it transitioned to mobile internet and established its own innovative brand “iHealth” in Silicon Valley, launching a mobile-connected blood pressure monitor compatible with Apple phones. This was strongly supported by Apple Inc., making its way into Apple’s official online website and offline direct sales channels. The company has since released wearable devices for personal health covering blood pressure, blood sugar, blood oxygen, ECG, heart rate, weight, body fat, sleep, and exercise, and received a $25 million strategic investment from Xiaomi Technology, becoming a partner in the Xiaomi ecosystem.

In 2021, the company’s self-test OTC kit for COVID-19 antigen detection, branded under iHealth, received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA), making it the second Chinese company to receive such an EUA for COVID-19 antigen self-test products.

The company focuses on diabetes management as an entry point to implement the “Internet + Medical” strategy. Through the integration of “smart hardware + APP + cloud platform”, they realize the integration of software and hardware, offline and online, and inside and outside the hospital, extending chronic disease management and diagnosis from inside the hospital to outside. The average hemoglobin A1c compliance rate increased from about 30% at baseline to about 60%, with a decrease in the adverse event rate to below 5% and a standardized management rate of 70%.

Internationally, Andon operates on an OEM/ODM business model. Their products are exported to countries like Germany, UK, France, USA, Italy, Spain, Portugal, Netherlands, Belgium, Sweden, Norway, Denmark, Finland, Turkey, Poland, Hungary, Czech Republic, Bulgaria, Ukraine, Russia, Australia, New Zealand, Canada, Brazil, Chile, Colombia, Paraguay, Peru, Venezuela, Israel, Nigeria, India, Malaysia, Singapore, Indonesia, Korea, and more – spanning over 100 countries. In the German market alone, they have secured a 50% market share, breaking the monopoly held by Japanese and Taiwanese manufacturers in the electronic blood pressure monitor industry, and becoming a mainland Chinese company that can compete with them.

The company has set up subsidiaries in Silicon Valley, Paris, Beijing, and Singapore. They acquired eDevice, a leading French mobile medical company that provides device connectivity and remote monitoring services for cardiac pacemaker patients, for 700 million yuan. In 2017, Andon Medical participated in setting up an overseas acquisition fund and acquired the U.S.-based mobile medical company, Care Innovations (“CI”).

Best-selling Products from the Andon Brand：